Results 101 to 110 of about 6,798 (212)

Clinical Development of Experimental Therapies for Malignant Glioma

open access: yesSultan Qaboos University Medical Journal, 2011
Advances in medical and surgical treatments in the last two to three decades have resulted in quantum leaps in the overall survival of patients with many types of non-central nervous system (CNS) malignant disease, while survival of patients with ...
Nikolai G Rainov, Volkmar Heidecke
doaj  

Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin

open access: yes, 2016
Hematopoietic stem cell transplantation (HSCT) offers curative therapy for patients with hemoglobinopathies, congenital immunodeficiencies, and other conditions, possibly including AIDS.
Scadden, David   +12 more
core   +1 more source

Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule

open access: yes, 1992
SUMMARY A ricin A chain immunotoxin, SEN36-ricin A chain, directed against the neural cell adhesion molecule (N-CAM) had no selective cytotoxic activity against three different small cell lung cancer (SCLC) cell lines in tissue culture ...
R A STAHEL   +2 more
core   +1 more source

In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours

open access: yes, 2013
11 p.-6 fig.TGF-beta superfamily co-receptors are emerging as targets for cancer therapy, acting both directly on cells and indirectly on the tumour neovasculature.
Córdoba-Díaz, Damián   +9 more
core   +1 more source

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia

open access: yes, 2017
Key Points A phase 1 trial of the anti-CD22 immunotoxin moxetumomab pasudotox was conducted in children with ALL. A 32% objective response rate was observed, including 11 composite complete responses (23%), 5 of which were minimal residual
James A. Whitlock   +11 more
core   +1 more source

CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model

open access: yes, 2022
S.5833-5838Macrophages are known to play a key role during inflammation in rheumatoid arthritis (RA). Inflammatory macrophages have increased expression of CD64, the high-affinity receptor for IgG.
Walraven, V.   +7 more
core  

immunotoxin

open access: yes
Citation: 'immunotoxin' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13326 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms.
openaire   +1 more source

In Silico Design and Structural Characterization of 4D5mocB-PE24: A Novel Immunotoxin for EpCAM-Targeted Cancer Therapy

open access: yes
Introduction: Antibody-based immunotoxins are a promising novel therapeutic approach aimed at targeted cancer therapy, utilizing the target specificity of antibody fragments attached to a potent cytotoxic ...
Safar Farajnia   +4 more
core   +1 more source

Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin

open access: yes, 1987
The studies described in this report demonstrate that 1-adamantanamine hydrochloride (amantadine) is a potent enhancer of the cytotoxic activity of the anti-pan-T lymphocyte (CD5) T101 monoclonal antibody conjugated to purified ricin A-chain (T101 ...
S. Villa   +4 more
core   +1 more source

Tailoring Immunotoxin AS Anticancer Drug [PDF]

open access: yes, 1989
The conventional treatments for cancer have been considered unsatisfatory, with limited efficiency in terms of discriminative cancer cell adverse reaction against the normal compartments, a number of immunological approaches had been implemented.
Asikin, N. (Nur)   +6 more
core  

Home - About - Disclaimer - Privacy